Total Payments
$141,072
2024 Payments
$4,607
Companies
18
Transactions
110
Medicare Patients
1,130
Medicare Billing
$209,891
Payment Breakdown by Category
Consulting$71,399 (50.6%)
Research$51,258 (36.3%)
Other$10,250 (7.3%)
Travel$5,654 (4.0%)
Food & Beverage$2,047 (1.5%)
Education$463.73 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $71,399 | 45 | 50.6% |
| Unspecified | $51,258 | 19 | 36.3% |
| Honoraria | $8,750 | 1 | 6.2% |
| Travel and Lodging | $5,654 | 16 | 4.0% |
| Food and Beverage | $2,047 | 27 | 1.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500 | 1 | 1.1% |
| Education | $463.73 | 1 | 0.3% |
Payments by Type
General
$89,814
91 transactions
Research
$51,258
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $30,431 | 3 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $24,432 | 12 | $0 (2024) |
| Boehringer Ingelheim Finland Ky | $23,500 | 26 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $20,121 | 9 | $0 (2023) |
| Merck Sharp & Dohme LLC | $18,192 | 19 | $0 (2024) |
| PFIZER INC. | $12,137 | 12 | $0 (2023) |
| Ventana Medical Systems, Inc. | $3,352 | 8 | $0 (2017) |
| Millennium Pharmaceuticals, Inc. | $3,051 | 2 | $0 (2017) |
| Eisai Inc. | $1,719 | 1 | $0 (2020) |
| Amgen Inc. | $1,699 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,607 | 4 | Novartis Pharmaceuticals Corporation ($2,409) |
| 2023 | $20,008 | 14 | E.R. Squibb & Sons, L.L.C. ($10,832) |
| 2022 | $3,820 | 2 | PFIZER INC. ($3,820) |
| 2021 | $13,508 | 8 | Novartis Pharmaceuticals Corporation ($6,038) |
| 2020 | $30,817 | 6 | Eli Lilly and Company ($20,661) |
| 2019 | $957.45 | 7 | Merck Sharp & Dohme Corporation ($450.00) |
| 2018 | $31,687 | 24 | Eli Lilly and Company ($9,362) |
| 2017 | $35,668 | 45 | Boehringer Ingelheim Finland Ky ($15,000) |
All Payment Transactions
110 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 09/14/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $62.29 | General |
| Category: VACCINE | ||||||
| 07/11/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | — | Cash or cash equivalent | $1,204.72 | Research |
| Study: HEOR • Category: Oncology | ||||||
| 06/04/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $1,204.72 | Research |
| Study: HEOR | ||||||
| 10/25/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $1,057.34 | General |
| 10/25/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $377.80 | General |
| 10/20/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $44.06 | General |
| 10/19/2023 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/13/2023 | E.R. Squibb & Sons, L.L.C. | — | Honoraria | Cash or cash equivalent | $8,750.00 | General |
| 09/06/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $647.00 | General |
| 06/05/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,220.00 | General |
| 05/19/2023 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB MULTI PRODUCT PF07265807 BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/10/2023 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | — | Cash or cash equivalent | $4,045.33 | Research |
| Study: TMT-AB -113851-Relapse-Free Survival with Adjuvant Dabrafenib/Trametinib Therapy After Relapse on Adjuvant Checkpoint Inhibitor Therapy and Subsequent Surgical Resection in Patients with BRAF V600-mutated Stage III/IV Melanoma: Interim Analysis-ESMO • Category: Oncology | ||||||
| 05/09/2023 | PFIZER INC. | BRAFTOVI (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: ENCORAFENIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/03/2023 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $56.00 | General |
| 04/05/2023 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB MULTI PRODUCT PF07265807 BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/14/2023 | PFIZER INC. | BRAFTOVI (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: ENCORAFENIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/12/2023 | PFIZER INC. | BRAFTOVI (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: ENCORAFENIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/03/2022 | PFIZER INC. | MEKTOVI (Drug), BRAFTOVI | — | In-kind items and services | $620.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/18/2022 | PFIZER INC. | BRAFTOVI (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/19/2021 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $3,200.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/06/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 09/21/2021 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/09/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,812.50 | General |
| 06/25/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1 STUDY OF AN ERK1/2 INHIBITOR (LY3214996) ADMINISTERED ALONE OR IN COMBINATION WITH OTHER AGENTS IN ADVANCED CANCER | Eli Lilly and Company | $30,431 | 3 |
| ENCORAFENIB AND BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,290 | 5 |
| TMT-AB -113851-Relapse-Free Survival with Adjuvant Dabrafenib/Trametinib Therapy After Relapse on Adjuvant Checkpoint Inhibitor Therapy and Subsequent Surgical Resection in Patients with BRAF V600-mutated Stage III/IV Melanoma: Interim Analysis-ESMO | Novartis Pharmaceuticals Corporation | $4,045 | 1 |
| HEOR | Novartis Pharmaceuticals Corporation | $2,409 | 2 |
| ENCORAFENIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,930 | 4 |
| ENCORAFENIB MULTI PRODUCT PF07265807 BINIMETINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| REAL-WORLD CHARACTERIZATION OF PYREXIA IN PATIENTS WITH MELANOMA TREATED WITH DABRAFENIB AND TRAMETINIB | Novartis Pharmaceuticals Corporation | $1,350 | 1 |
| AMG 232 FIH | Amgen Inc. | $922.22 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 235 | 479 | $247,677 | $48,007 |
| 2022 | 5 | 260 | 529 | $263,757 | $53,839 |
| 2021 | 8 | 348 | 706 | $297,721 | $72,955 |
| 2020 | 5 | 287 | 494 | $166,927 | $35,089 |
Total Patients
1,130
Total Services
2,208
Medicare Billing
$209,891
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 115 | 280 | $170,915 | $33,163 | 19.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 107 | 154 | $62,272 | $11,928 | 19.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 45 | $14,490 | $2,917 | 20.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 105 | 273 | $162,613 | $33,600 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 118 | 190 | $75,786 | $15,074 | 19.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 35 | $14,551 | $3,043 | 20.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 12 | 19 | $7,567 | $1,428 | 18.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 12 | $3,240 | $693.79 | 21.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 122 | 319 | $158,671 | $40,096 | 25.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 126 | 215 | $73,400 | $18,313 | 25.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 76 | $31,832 | $6,794 | 21.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 19 | 24 | $8,178 | $2,095 | 25.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $8,967 | $1,907 | 21.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 30 | $8,670 | $1,866 | 21.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 17 | 17 | $3,907 | $1,001 | 25.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 14 | 14 | $4,096 | $883.40 | 21.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 83 | 165 | $77,344 | $15,079 | 19.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 120 | 225 | $71,893 | $14,928 | 20.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 36 | 45 | $5,339 | $2,033 | 38.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 34 | 41 | $8,414 | $1,783 | 21.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 14 | 18 | $3,937 | $1,267 | 32.2% |
About Dr. Ryan Sullivan, MD
Dr. Ryan Sullivan, MD is a Internal Medicine healthcare provider based in Cambridge, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1881696003.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ryan Sullivan, MD has received a total of $141,072 in payments from pharmaceutical and medical device companies, with $4,607 received in 2024. These payments were reported across 110 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($71,399).
As a Medicare-enrolled provider, Sullivan has provided services to 1,130 Medicare beneficiaries, totaling 2,208 services with total Medicare billing of $209,891. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Cambridge, MA
- Active Since 06/01/2005
- Last Updated 03/24/2009
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1881696003
Products in Payments
- TRADJENTA (Drug) $23,500
- MEKINIST (Drug) $15,627
- BRAFTOVI (Drug) $11,480
- VENTANA RESEARCH & DEVELOPMENT (Device) $3,352
- ENTYVIO (Biological) $3,051
- Lenvima (Drug) $1,719
- TAFINLAR (Drug) $1,350
- Non-Covered Product (Drug) $818.99
- MEKTOVI (Drug) $620.00
- Proleukin (Drug) $369.11
- KEYTRUDA (Biological) $85.86
- Rubraca (Drug) $13.07
- Herceptin (Biological) $7.22
- Perjeta (Biological) $3.64
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Cambridge
Prof. Alan Garber, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $7.2M
Internal Medicine $7.2M
Joanna Haas, M.d, M.D
Internal Medicine — Payments: $279,060
Internal Medicine $279,060
Dr. William Li, M.d, M.D
Internal Medicine — Payments: $237,421
Internal Medicine $237,421
Amy Colson, Md, MD
Internal Medicine — Payments: $158,226
Internal Medicine $158,226
Dr. Madalon Meany, Md, MD
Internal Medicine — Payments: $122,795
Internal Medicine $122,795
Nour Tashtish
Internal Medicine — Payments: $81,657
Internal Medicine $81,657